| Project/Area Number |
15591163
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Embryonic/Neonatal medicine
|
|---|
| Research Institution | Showa University School of Medicine |
|---|
Principal Investigator |
SEKIZAWA Akihiko Showa Univ, School of Med, MD, Associate Professor, 医学部, 講師 (10245839)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ICHIZUKA Kiyotake Showa Univ, School of Med, MD, Assistant Professor, 医学部, 助手 (00338451)
MATSUOKA Ryu Showa Univ, School of Med, MD, Assistant Professor, 医学部, 助手 (20349111)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2004: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2003: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | cell-free DNA / placental damage / preeclampsia / fetal diagnosis / nonivasive approach / gene test / 遺伝子検査 / 妊娠中毒症 / DNA / 母体血 / 浮遊DNA / DYS14遣伝子 / real time PCR |
|---|
| Research Abstract |
Circulating fetal DNA in maternal plasma can be used for both fetal genetic testing and evaluation of complications of pregnancy. As a prenatal genetic test, the greatest feature of this approach is the lack of risk. This approach was applied to the diagnosis of fetal gender, fetal RhD blood type, and fetal single-gene-disorders. However, this plasma DNA approach only allows examination of disorders where the gene of interest is present in the fetal genome but absent from maternal DNA. Since the majority of fetal DNA probably originates from villous trophoblasts, concentrations can be used for the evaluation of damage to trophoblasts, particularly in the pathological complications of pregnancy, such as pre-eclampsia, invasive placenta, hyperemesis gravidarum, and trisomy 21. Fetal DNA in the plasma of pregnant women thus offers a new source of data that can be used in various clinical settings.
|
